Literature DB >> 20507321

DNA methylation of interferon regulatory factors in gastric cancer and noncancerous gastric mucosae.

Masaki Yamashita1, Minoru Toyota, Hiromu Suzuki, Masanori Nojima, Eiichiro Yamamoto, Seiko Kamimae, Yoshiyuki Watanabe, Masahiro Kai, Hirofumi Akashi, Reo Maruyama, Yasushi Sasaki, Hiroo Yamano, Tamotsu Sugai, Yasuhisa Shinomura, Kohzoh Imai, Takashi Tokino, Fumio Itoh.   

Abstract

Interferon regulatory factors (IRFs) are transcription factors known to play key roles in innate and adaptive immune responses, cell growth, apoptosis, and development. Their function in tumorigenesis of gastric cancer remains to be determined, however. In the present study, therefore, we examined epigenetic inactivation of IRF1-9 in a panel of gastric cancer cell lines. We found that expression of IRF4, IRF5, and IRF8 was frequently suppressed in gastric cancer cell lines; that methylation of the three genes correlated with their silencing; and that treating the cells with the demethylating agent 5-aza-2'-deoxycytidine (DAC) restored their expression. Expression of IRF5 in cancer cells was enhanced by the combination of DAC treatment and adenoviral vector-mediated expression of p53, p63, or p73. Interferon-gamma-induced expression of IRF8 was also enhanced by DAC. Moreover, treating gastric cancer cells with DAC enhanced the suppressive effects of interferon-alpha, interferon-beta, and interferon-gamma on cell growth. Among a cohort of 455 gastric cancer and noncancerous gastric tissue samples, methylation of IRF4 was frequently observed in both gastric cancer specimens and noncancerous specimens of gastric mucosa from patients with multiple gastric cancers, which suggests IRF4 methylation could be a useful molecular marker for diagnosing recurrence of gastric cancers. Our findings indicate that epigenetic IRF inactivation plays a key role in tumorigenesis of gastric cancer, and that inhibition of DNA methylation may restore the antitumor activity of interferons through up-regulation of IRFs.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20507321     DOI: 10.1111/j.1349-7006.2010.01581.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  22 in total

1.  Decitibine improve the efficiency of anti-PD-1 therapy via activating the response to IFN/PD-L1 signal of lung cancer cells.

Authors:  Qi Lai; Haiyong Wang; Angui Li; Yinhui Xu; Liang Tang; Qiang Chen; Chunfang Zhang; Yang Gao; Jianfei Song; Zhenzong Du
Journal:  Oncogene       Date:  2018-02-09       Impact factor: 9.867

2.  Methylator phenotype of malignant germ cell tumours in children identifies strong candidates for chemotherapy resistance.

Authors:  J N Jeyapalan; D A Mohamed Noor; S-H Lee; C L Tan; V A Appleby; J P Kilday; R D Palmer; E C Schwalbe; S C Clifford; D A Walker; M J Murray; N Coleman; J C Nicholson; P J Scotting
Journal:  Br J Cancer       Date:  2011-06-28       Impact factor: 7.640

3.  Interferon-gamma directly mediates developmental biliary defects.

Authors:  Shuang Cui; Steven F Eauclaire; Randolph P Matthews
Journal:  Zebrafish       Date:  2013-02-28       Impact factor: 1.985

4.  Interferon regulatory factor 5-dependent immune responses in the draining lymph node protect against West Nile virus infection.

Authors:  Larissa B Thackray; Bimmi Shrestha; Justin M Richner; Jonathan J Miner; Amelia K Pinto; Helen M Lazear; Michael Gale; Michael S Diamond
Journal:  J Virol       Date:  2014-07-16       Impact factor: 5.103

5.  Characterization of DNA hypermethylation in two cases of peritoneal mesothelioma.

Authors:  Ryota Hama; Yoshiyuki Watanabe; Kanako Shinada; Yosuke Yamada; Yuka Ogata; Yoshihito Yoshida; Tomohiro Tamura; Tetsuya Hiraishi; Ritsuko Oikawa; Jo Sakurai; Tadateru Maehata; Hirotaka Koizumi; Fumio Itoh
Journal:  Tumour Biol       Date:  2012-07-27

Review 6.  Chromatin Landscape of the IRF Genes and Role of the Epigenetic Reader BRD4.

Authors:  Mahesh Bachu; Anup Dey; Keiko Ozato
Journal:  J Interferon Cytokine Res       Date:  2016-07       Impact factor: 2.607

7.  IRF-8 controls melanoma progression by regulating the cross talk between cancer and immune cells within the tumor microenvironment.

Authors:  Fabrizio Mattei; Giovanna Schiavoni; Paola Sestili; Francesca Spadaro; Alessandra Fragale; Antonella Sistigu; Valeria Lucarini; Massimo Spada; Massimo Sanchez; Stefania Scala; Angela Battistini; Filippo Belardelli; Lucia Gabriele
Journal:  Neoplasia       Date:  2012-12       Impact factor: 5.715

8.  Epigenetic silencing of IRF7 and/or IRF5 in lung cancer cells leads to increased sensitivity to oncolytic viruses.

Authors:  Qunfang Li; Michael A Tainsky
Journal:  PLoS One       Date:  2011-12-14       Impact factor: 3.240

9.  miR-23a targets interferon regulatory factor 1 and modulates cellular proliferation and paclitaxel-induced apoptosis in gastric adenocarcinoma cells.

Authors:  Xue Liu; Jing Ru; Jian Zhang; Li-hua Zhu; Min Liu; Xin Li; Hua Tang
Journal:  PLoS One       Date:  2013-06-10       Impact factor: 3.240

10.  PLXNC1: A Novel Potential Immune-Related Target for Stomach Adenocarcinoma.

Authors:  Zhizhan Ni; Chenshen Huang; Hongmei Zhao; Jinzhe Zhou; Muren Hu; Qing Chen; Bujun Ge; Qi Huang
Journal:  Front Cell Dev Biol       Date:  2021-07-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.